Zora-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the treatment of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone is a dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The combination of these two agents in Zora-DSR Capsule offers a synergistic effect by addressing both the motility dysfunction and acid hypersecretion, thereby improving symptomatic relief and promoting mucosal healing. This medication is indicated for patients experiencing symptoms of acid reflux accompanied by delayed gastric emptying or dyspepsia. It should be used under medical supervision, with caution advised in patients with cardiac arrhythmias, liver impairment, or those taking medications that may interact with Domperidone or Rabeprazole. Adherence to prescribed dosage and duration is essential to maximize therapeutic outcomes and minimize adverse effects.